Cargando…

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy

Affibody molecules are engineered scaffold proteins, which demonstrated excellent binding to selected tumor-associated molecular abnormalities in vivo and highly sensitive and specific radionuclide imaging of Her2-expressing tumors in clinics. Recently, we have shown that peptide nucleic acid (PNA)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vorobyeva, Anzhelika, Westerlund, Kristina, Mitran, Bogdan, Altai, Mohamed, Rinne, Sara, Sörensen, Jens, Orlova, Anna, Tolmachev, Vladimir, Karlström, Amelie Eriksson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018533/ https://www.ncbi.nlm.nih.gov/pubmed/29942011 http://dx.doi.org/10.1038/s41598-018-27886-0

Ejemplares similares

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
por: Honarvar, Hadis, et al.
Publicado: (2016)

Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
por: Myrhammar, Anders, et al.
Publicado: (2020)

Comparative Evaluation of Novel (177)Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
por: Tano, Hanna, et al.
Publicado: (2021)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
por: Rosestedt, Maria, et al.
Publicado: (2019)

Influence of composition of cysteine-containing peptide-based chelators on biodistribution of (99m)Tc-labeled anti-EGFR affibody molecules
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
por: Altai, Mohamed, et al.
Publicado: (2018)

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of (68)Ga-Labeled Tracers
por: Dahlsson Leitao, Charles, et al.
Publicado: (2019)

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules
por: Garousi, Javad, et al.
Publicado: (2020)

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model
por: Mitran, Bogdan, et al.
Publicado: (2018)

Cyclic versus Noncyclic Chelating Scaffold for (89)Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
por: Summer, Dominik, et al.
Publicado: (2017)

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
por: Rinne, Sara S., et al.
Publicado: (2019)

Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development
por: Tolmachev, Vladimir, et al.
Publicado: (2022)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
por: Yin, Wen, et al.
Publicado: (2021)

Evaluation of (99m)Tc-Z(IGF1R:4551)-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression
por: Mitran, Bogdan, et al.
Publicado: (2014)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts
por: Garousi, Javad, et al.
Publicado: (2019)

Influence of Macrocyclic Chelators on the Targeting Properties of (68)Ga-Labeled Synthetic Affibody Molecules: Comparison with (111)In-Labeled Counterparts
por: Strand, Joanna, et al.
Publicado: (2013)

Preclinical Evaluation of (99m)Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Affibody-mediated PET imaging of HER3 expression in malignant tumours
por: Rosestedt, Maria, et al.
Publicado: (2015)

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
por: Xu, Tianqi, et al.
Publicado: (2020)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Preclinical Evaluation of a New Format of (68)Ga- and (111)In-Labeled Affibody Molecule Z(IGF-1R:4551) for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
por: Liu, Yongsheng, et al.
Publicado: (2022)

Increase in negative charge of (68)Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules
por: Rinne, Sara S., et al.
Publicado: (2019)

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with (64)Cu Using NOTA and NODAGA
por: Tolmachev, Vladimir, et al.
Publicado: (2017)

Molecular design of radiocopper-labelled Affibody molecules
por: Tolmachev, Vladimir, et al.
Publicado: (2018)

Affibody Molecules as Targeting Vectors for PET Imaging
por: Tolmachev, Vladimir, et al.
Publicado: (2020)

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
por: Xu, Tianqi, et al.
Publicado: (2022)

Stability Enhancement of a Dimeric HER2-Specific Affibody Molecule through Sortase A-Catalyzed Head-to-Tail Cyclization
por: Westerlund, Kristina, et al.
Publicado: (2021)

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1
por: Vorobyeva, Anzhelika, et al.
Publicado: (2020)

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
por: Dahlsson Leitao, Charles, et al.
Publicado: (2020)

Comparative evaluation of tumor targeting using the anti-HER2 ADAPT scaffold protein labeled at the C-terminus with indium-111 or technetium-99m
por: Garousi, Javad, et al.
Publicado: (2017)

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2020)

Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
por: Strand, Joanna, et al.
Publicado: (2015)

Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2
por: Vorobyeva, Anzhelika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5kodgv5ch19dh1ku6voss6s38t